glp-1-based treatments approved for weight loss 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ Alarming rise in weight loss

as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who have not achieved adequate control with metformin or sitagliptin monotherapy, or after unsuccessful combination therapy with two drugs

The majority of organizations (76 percent) provide GLP-1 drug coverage for diabetesthe original intended use for drugs including Ozempicfar outpacing the percentage of those providing coverage for weight loss, according to a new survey of 200 employers out from the International Foundation of Employee Benefit Plans (IFEBP)

CJC-1295 no DAC Ipamorelin peptide blend is frequently referenced in research workflows focused on peptide interaction models, endocrine signaling mechanisms, and combination-based peptide research

Vial Duration Calculator Calculate how many days a reconstituted vial will last based on your dosing protocol